Effects of depression on the cytokine profile in drug naïve first-episode psychosis

Schizophrenia Research

Volumn 164, Issue 1-3, 2015, Pages 53-58

  Noto, Cristiano ^a,b   Ota, Vanessa Kiyomi ^a   Santoro, Marcos Leite ^a   Ortiz, Bruno B ^a   Rizzo, Lucas B ^a   Higuchi, Cinthia Hiroko ^a   Cordeiro, Quirino ^a,b   Belangero, Sintia Iole ^a   Bressan, Rodrigo Affonseca ^a   Gadelha, Ary ^a   Maes, Michael ^c,d,e   Brietzke, Elisa ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^c DEAKIN UNIVERSITY   (Australia)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Cytokines; Depression; Drug na ve; First episode psychosis (FEP); Schizophrenia

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CELL ACTIVATION; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PSYCHOSIS; REGULATORY T LYMPHOCYTE; SYMPTOM; TH1 CELL; TH2 CELL; ANALYSIS OF VARIANCE; BLOOD; CHI SQUARE DISTRIBUTION; COMPLICATION; PREDICTIVE VALUE; YOUNG ADULT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CYTOKINES; DEPRESSION; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 84929267461     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.01.026     Document Type: Article

References (43)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3(4):247-251.
2. an der Heiden W., Konnecke R., Maurer K., Ropeter D., Hafner H. Depression in the long-term course of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255(3):174-184.
3. Anderson G., Berk M., Dodd S., Bechter K., Altamura A.C., Dell'osso B., Kanba S., Monji A., Fatemi S.H., Buckley P., Debnath M., Das U.N., Meyer U., Muller N., Kanchanatawan B., Maes M. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:1-4.
4. Anderson G., Maes M., Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:101-114.
5. Andrade E., Rizzo L.B., Noto C., Ota V.K., Gadelha A., Daruy-Filho L., Tasso B.C., Mansur R.B., Moraes G.D., Cordeiro Q., Belangero S.I., Bressan R.A., Grassi-Oliveira R., Brietzke E. Hair Cortisol Analysis in Drug-naïve First-episode Psychosis Individuals 2015, (in preparation).
6. Asevedo E., Gadelha A., Noto C., Mansur R.B., Zugman A., Belangero S.I., Berberian A.A., Scarpato B.S., Leclerc E., Teixeira A.L., Gama C.S., Bressan R.A., Brietzke E. Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. J. Psychiatr. Res. 2013, 47(10):1376-1382.
7. Bauer S., Kerr B.J., Patterson P.H. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat. Rev. Neurosci. 2007, 8(3):221-232.
8. Bjorkenstam C., Bjorkenstam E., Hjern A., Boden R., Reutfors J. Suicide in first episode psychosis: a nationwide cohort study. Schizophr. Res. 2014, 157(1-3):1-7. (Epub 2014 Jun 2). 10.1016/j.schres.2014.05.010.
9. Boulanger L.M., Shatz C.J. Immune signalling in neural development, synaptic plasticity and disease. Nat. Rev. Neurosci. 2004, 5(7):521-531.
10. Bressan R.A., Chaves A.C., Shirakawa I., de Mari J. Validity study of the Brazilian version of the Calgary Depression Scale for Schizophrenia. Schizophr. Res. 1998, 32(1):41-49.
11. Challis S., Nielssen O., Harris A., Large M. Systematic meta-analysis of the risk factors for deliberate self-harm before and after treatment for first-episode psychosis. Acta Psychiatr. Scand. 2013, 127(6):442-454.
12. Conley R.R., Ascher-Svanum H., Zhu B., Faries D.E., Kinon B.J. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr. Res. 2007, 90(1-3):186-197.
13. Ding M., Song X., Zhao J., Gao J., Li X., Yang G., Wang X., Harrington A., Fan X., Lv L. Activation of Th17 cells in drug naive, first episode schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 51:78-82.
14. Golan H., Levav T., Mendelsohn A., Huleihel M. Involvement of tumor necrosis factor alpha in hippocampal development and function. Cereb. Cortex 2004, 14(1):97-105.
15. Gozdzik-Zelazny A., Borecki L., Pokorski M. Depressive symptoms in schizophrenic patients. Eur. J. Med. Res. 2011, 16(12):549-552.
16. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kuhn M., Schuld A., Pollmacher T. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res. 1999, 33(5):407-418.
17. Insel T.R. Rethinking schizophrenia. Nature 2010, 468(7321):187-193.
18. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
19. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 2012, 36(2):764-785.
20. MacDowell K.S., Garcia-Bueno B., Madrigal J.L., Parellada M., Arango C., Mico J.A., Leza J.C. Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. Int. J. Neuropsychopharmacol. 2013, 16(1):121-135.
21. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 1995, 19(1):11-38.
22. Maes M., Bosmans E., Suy E., Vandervorst C., De Jonckheere C., Raus J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 1990, 24(3):115-120.
23. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G., Pioli R., Boin F., Kenis G., Bosmans E., de Jongh R., Lin A., Racagni G., Altamura C.A. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur. Neuropsychopharmacol. 2000, 10(2):119-124.
24. Maes M., Mihaylova I., Kubera M., Ringel K. Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 36(1):169-175.
25. Maes M., Song C., Yirmiya R. Targeting IL-1 in depression. Expert Opin. Ther. Targets 2012, 16(11):1097-1112.
26. Maes M., Anderson G., Kubera M., Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?. Expert Opin. Ther. Targets 2014, 18(5):495-512.
27. Meyer U. Developmental neuroinflammation and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:20-34.
28. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
29. Noto C.S., Gadelha A., Belangero S.I., Smith M.A., de Aguiar B.W., Panizzuti B., Mari Jde J., Gama C.S., Bressan R.A., Brietzke E. Association of biomarkers and depressive symptoms in schizophrenia. Neurosci. Lett. 2011, 505(3):282-285.
30. Noto C., Gadelha A., Belangero S.I., Spindola L.M., Rocha N.P., de Miranda A.S., Teixeira A.L., Cardoso Smith M.A., de Jesus Mari J., Bressan R.A., Brietzke E. Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. J. Psychiatr. Res. 2013, 47(4):467-471.
31. Noto C., Rizzo L.B., Mansur R.B., McIntyre R.S., Maes M., Brietzke E. Targeting the inflammatory pathway as a therapeutic tool for major depression. Neuroimmunomodulation 2014, 21(2-3):131-139.
32. Noto C., Ota V.K., Gouveia E.S., Rizzo L.B., Spindola L.M., Honda P.H., Cordeiro Q., Belangero S.I., Bressan R.A., Gadelha A., Maes M., Brietzke E. Effects of risperidone on cytokine profile in drug naive first episode psychosis. Int. J. Neuropsychopharmacol. 2014, (pii: pyu042, Epub ahead of print). 10.1093/ijnp/pyu042.
33. Ota V.K., Noto C., Gadelha A., Santoro M.L., Ortiz B.B., Andrade E.H., Tasso B.C., Spindola L.M., Silva P.N., Abilio V.C., Smith Mde A., Sato J.R., Brietzke E., Cordeiro Q., Bressan R.A., Belangero S.I. Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: a follow-up study in antipsychotic-naive patients with first-episode psychosis. J. Psychiatr. Res. 2014, 56:130-136.
34. Ota V.K., Noto C., Gadelha A., Santoro M.L., Spindola L.M., Gouvea E.S., Stilhano R.S., Ortiz B.B., Silva P.N., Sato J.R., Han S.W., Cordeiro Q., Bressan R.A., Belangero S.I. Changes in gene expression and methylation in the blood of patients with first-episode psychosis. Schizophr. Res. 2014, 159(2-3):358-364. (Epub 2014 Sep 28). 10.1016/j.schres.2014.09.008.
35. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63(8):801-808.
36. Schennach R., Riedel M., Obermeier M., Seemuller F., Jager M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkotter J., Heuser I., Maier W., Lemke M.R., Ruther E., Klingberg S., Gastpar M., Moller H. What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?. Eur. Psychiatry 2015, 30(1):43-50. (Epub 2014 Dec 22). 10.1016/j.eurpsy.2014.11.001.
37. Seruga B., Zhang H., Bernstein L.J., Tannock I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 2008, 8(11):887-899.
38. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypotheses 1995, 45(2):135-141.
39. Sonmez N., Rossberg J.I., Evensen J., Barder H.E., Haahr U., Ten Velden Hegelstad W., Joa I., Johannessen J.O., Langeveld H., Larsen T.K., Melle I., Opjordsmoen S., Rund B.R., Simonsen E., Vaglum P., McGlashan T., Friis S. Depressive symptoms in first-episode psychosis: a 10-year follow-up study. Early Interv. Psychiatry 2014, (Epub ahead of print). 10.1111/eip.12163.
40. Tourjman V., Kouassi E., Koue M.E., Rocchetti M., Fortin-Fournier S., Fusar-Poli P., Potvin S. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr. Res. 2013, 151(1-3):43-47.
41. Upthegrove R., Birchwood M., Ross K., Brunett K., McCollum R., Jones L. The evolution of depression and suicidality in first episode psychosis. Acta Psychiatr. Scand. 2010, 122(3):211-218.
42. Upthegrove R., Manzanares-Teson N., Barnes N.M. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr. Res. 2014, 155(1-3):101-108.
43. Zajkowska Z., Mondelli V. First-episode psychosis: an inflammatory state?. Neuroimmunomodulation 2014, 21(2-3):102-108.